What's going on with Danish stocks?

What's going on with Danish stocks?

Equities 4 minutes to read
Peter Garnry

Chief Investment Strategist

Summary:  A localized earthquake of negative headlines has shaken the share prices of some of Denmark's largest companies today. The timing is coincidental but the impact, with Copenhagen down 3.6% as of this writing, is very real.


On this slight down day in global equities (-0.4%)  a financial earthquake is taken place in a small corner of the equity market. The leading Danish benchmark index on equities, the OMXC25, is down 3.6% driven by a bunch of company-specific headlines hitting several companies on the same day.

It is ultimately a coincidence, but nevertheless represents obvious pain for investors in this market. It is particularly painful as the OMXC25 has been one of the best markets for years, awakening foreign interest in this tiny little equity market.

Let’s look at some of today’s events:

• Novo Nordisk shares are down 9% (biggest index weight at 15.4%) as Eli Lilly has announced test results for an experimental diabetes drug to cut patients’ weight and reduce blood-sugar levels. If Eli Lilly pushes new drugs forward with these benefits it would threaten Novo Nordisk’s current position in this market.

• Danske Bank shares are down 4% as the US Department of Justice is now investigating the money laundering case. This follows similar moves in Denmark and Estonia, adding to the negative sentiment on Denmark’s largest bank.

• Ambu shares are down 15% as the new financial targets for FY'20 are disappointing the market. The shares are now down 50% from the peak in August as the previous investor darling has seen its price target being cut by several sell-side analysts with investor concerns over management only bolstering the sell-off. Ambu was not long ago priced at the same valuation (on free cash flow yield) as Amazon, indicating strong investor confidence, but now it seems investors are having second thoughts.


The fact that these things are all happening on the same day is, of course, random. Danish equities are still of high quality relative to global equities overall, but sentiment is definitely negative with key technical levels being broken today.

Outside of Denmark, our view continues to be defensive on equities. US stocks are becoming outright unattractive as US credit offers a better risk-reward deal for investors. It is absolutely confusing to us to see new highs in US equities while the house of cards in emerging markets is collapsing. The escalating trade war resembles a new cold war between the US and China, and is worrying to say the least.

European banks are weak and Italy looks like a time bomb ready to go off. Meanwhile, the complacency is staggering with volatility still low given the risks on the horizon. We cannot state it enough how important it is for investors to set up their portfolios for more turbulence as 2019 approaches.

Quarterly Outlook

01 /

  • Equity outlook: The high cost of global fragmentation for US portfolios

    Quarterly Outlook

    Equity outlook: The high cost of global fragmentation for US portfolios

    Charu Chanana

    Chief Investment Strategist

  • Commodity Outlook: Commodities rally despite global uncertainty

    Quarterly Outlook

    Commodity Outlook: Commodities rally despite global uncertainty

    Ole Hansen

    Head of Commodity Strategy

  • Upending the global order at blinding speed

    Quarterly Outlook

    Upending the global order at blinding speed

    John J. Hardy

    Global Head of Macro Strategy

    We are witnessing a once-in-a-lifetime shredding of the global order. As the new order takes shape, ...
  • Asset allocation outlook: From Magnificent 7 to Magnificent 2,645—diversification matters, now more than ever

    Quarterly Outlook

    Asset allocation outlook: From Magnificent 7 to Magnificent 2,645—diversification matters, now more than ever

    Jacob Falkencrone

    Global Head of Investment Strategy

  • Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    Quarterly Outlook

    Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    John J. Hardy

    Global Head of Macro Strategy

  • Equity Outlook: The ride just got rougher

    Quarterly Outlook

    Equity Outlook: The ride just got rougher

    Charu Chanana

    Chief Investment Strategist

  • China Outlook: The choice between retaliation or de-escalation

    Quarterly Outlook

    China Outlook: The choice between retaliation or de-escalation

    Charu Chanana

    Chief Investment Strategist

  • Commodity Outlook: A bumpy road ahead calls for diversification

    Quarterly Outlook

    Commodity Outlook: A bumpy road ahead calls for diversification

    Ole Hansen

    Head of Commodity Strategy

  • FX outlook: Tariffs drive USD strength, until...?

    Quarterly Outlook

    FX outlook: Tariffs drive USD strength, until...?

    John J. Hardy

    Global Head of Macro Strategy

  • Fixed Income Outlook: Bonds Hit Reset. A New Equilibrium Emerges

    Quarterly Outlook

    Fixed Income Outlook: Bonds Hit Reset. A New Equilibrium Emerges

    Althea Spinozzi

    Head of Fixed Income Strategy

None of the information provided on this website constitutes an offer, solicitation, or endorsement to buy or sell any financial instrument, nor is it financial, investment, or trading advice. Saxo Capital Markets UK Ltd. (Saxo) and the Saxo Bank Group provides execution-only services, with all trades and investments based on self-directed decisions. Analysis, research, and educational content is for informational purposes only and should not be considered advice nor a recommendation. Access and use of this website is subject to: (i) the Terms of Use; (ii) the full Disclaimer; (iii) the Risk Warning; and (iv) any other notice or terms applying to Saxo’s news and research.

Saxo’s content may reflect the personal views of the author, which are subject to change without notice. Mentions of specific financial products are for illustrative purposes only and may serve to clarify financial literacy topics. Content classified as investment research is marketing material and does not meet legal requirements for independent research.

Before making any investment decisions, you should assess your own financial situation, needs, and objectives, and consider seeking independent professional advice. Saxo does not guarantee the accuracy or completeness of any information provided and assumes no liability for any errors, omissions, losses, or damages resulting from the use of this information.

Please refer to our full disclaimer for more details.

Saxo
40 Bank Street, 26th floor
E14 5DA
London
United Kingdom

Contact Saxo

Select region

United Kingdom
United Kingdom

Trade Responsibly
All trading carries risk. To help you understand the risks involved we have put together a series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. Read more
Additional Key Information Documents are available in our trading platform.

Saxo is a registered Trading Name of Saxo Capital Markets UK Ltd (‘Saxo’). Saxo is authorised and regulated by the Financial Conduct Authority, Firm Reference Number 551422. Registered address: 26th Floor, 40 Bank Street, Canary Wharf, London E14 5DA. Company number 7413871. Registered in England & Wales.

This website, including the information and materials contained in it, are not directed at, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in the United States, Belgium or any other jurisdiction where such distribution, publication, availability or use would be contrary to applicable law or regulation.

It is important that you understand that with investments, your capital is at risk. Past performance is not a guide to future performance. It is your responsibility to ensure that you make an informed decision about whether or not to invest with us. If you are still unsure if investing is right for you, please seek independent advice. Saxo assumes no liability for any loss sustained from trading in accordance with a recommendation.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Android is a trademark of Google Inc.

©   since 1992